Slow Capital Inc. Makes New Investment in GeneDx Holdings Corp. $WGS

Key Points

• Slow Capital Inc. has acquired approximately $3.6 million worth of shares in GeneDx Holdings Corp., increasing its stake to 0.14% as per its recent SEC filing.
• Other institutional investors have also significantly increased their investments, with T. Rowe Price and AllianceBernstein among the largest, boosting holdings during the first quarter.
• Despite recent insider sales totaling over $68 million, analysts maintain a consensus rating of "Moderate Buy" for GeneDx, with a target price averaging around $104.13.

Slow Capital Inc. purchased a new stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 39,150 shares of the company's stock, valued at approximately $3,614,000. Slow Capital Inc. owned 0.14% of GeneDx as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. T. Rowe Price Investment Management Inc. purchased a new stake in GeneDx in the 1st quarter worth approximately $44,614,000. Alliancebernstein L.P. grew its holdings in GeneDx by 3,054.5% in the first quarter. Alliancebernstein L.P. now owns 436,900 shares of the company's stock worth $38,694,000 after purchasing an additional 423,050 shares during the period. Wellington Management Group LLP lifted its holdings in shares of GeneDx by 202.3% during the first quarter. Wellington Management Group LLP now owns 425,647 shares of the company's stock valued at $37,697,000 after purchasing an additional 284,855 shares during the last quarter. American Century Companies Inc. purchased a new position in GeneDx during the first quarter valued at $23,877,000. Finally, Westfield Capital Management Co. LP bought a new stake in GeneDx in the first quarter worth $19,704,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at GeneDx

In related news, Director Casdin Capital, Llc sold 500,000 shares of the firm's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $120.90, for a total transaction of $60,450,000.00. Following the completion of the transaction, the director directly owned 3,007,164 shares of the company's stock, valued at approximately $363,566,127.60. This trade represents a 14.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Kevin Feeley sold 3,728 shares of the business's stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $121.47, for a total transaction of $452,840.16. Following the completion of the sale, the chief financial officer owned 8,755 shares in the company, valued at approximately $1,063,469.85. The trade was a 29.86% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 564,869 shares of company stock worth $68,279,628. 29.60% of the stock is currently owned by corporate insiders.

GeneDx Trading Up 1.6%

Shares of GeneDx stock opened at $120.19 on Tuesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.70 and a current ratio of 2.87. The company has a fifty day moving average of $119.53 and a 200 day moving average of $94.54. The company has a market capitalization of $3.45 billion, a P/E ratio of 2,403.80 and a beta of 1.98. GeneDx Holdings Corp. has a fifty-two week low of $48.95 and a fifty-two week high of $136.00.

GeneDx (NASDAQ:WGS - Get Free Report) last released its earnings results on Tuesday, July 29th. The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.40. GeneDx had a return on equity of 16.51% and a net margin of 0.39%.The firm had revenue of $102.69 million during the quarter, compared to analysts' expectations of $86.00 million. GeneDx has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Guggenheim restated a "buy" rating and issued a $115.00 price objective (up from $88.00) on shares of GeneDx in a report on Monday, June 30th. Wall Street Zen raised GeneDx from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Zacks Research downgraded GeneDx from a "strong-buy" rating to a "hold" rating in a research note on Thursday, October 2nd. Weiss Ratings reiterated a "sell (d)" rating on shares of GeneDx in a research note on Saturday, September 27th. Finally, Piper Sandler lifted their price target on shares of GeneDx from $120.00 to $140.00 and gave the stock an "overweight" rating in a research note on Thursday, September 11th. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, GeneDx has a consensus rating of "Moderate Buy" and an average target price of $104.13.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.